PAP
INDV icon

Persistent Asset Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Persistent Asset Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-587
Closed -$159K – 398
2025
Q4 		$159K Buy
+587
New +$17.9K 0.07% 239

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Persistent Asset Partners's INDV Position: Q1 2026 in Review

Persistent Asset Partners increased its Indivior Pharmaceuticals (INDV) stake by 298% in Q1 2026, buying an estimated $445K and bringing the position to 18,012 shares worth $549K. The position accounts for 0.2% of the portfolio, ranked #106.

Persistent Asset Partners first reported a position in INDV in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.41M in Q3 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Persistent Asset Partners held 18,012 shares of Indivior Pharmaceuticals worth $549K as of Q1 2026.
  • Persistent Asset Partners bought 13,482 Indivior Pharmaceuticals shares in Q1 2026, an estimated $445K.
  • Indivior Pharmaceuticals made up 0.2% of Persistent Asset Partners's portfolio in Q1 2026, its #106 holding.
  • Persistent Asset Partners first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Persistent Asset Partners's Indivior Pharmaceuticals position peaked at $1.41M in Q3 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.